Management of Ventilator-Dependent Infant with BPD
Rationale for Low-Dose Corticosteroids
- The American Academy of Pediatrics recommends low-dose dexamethasone therapy (<0.2 mg/kg per day) to facilitate extubation and decrease the incidence of short- and long-term adverse effects observed with higher doses in infants with bronchopulmonary dysplasia (BPD) 1
- Low-dose dexamethasone (0.05-0.2 mg/kg/day) has demonstrated effectiveness in facilitating extubation without the severe adverse effects seen with higher doses, with a study showing 12 of 16 babies receiving extremely low-dose dexamethasone were successfully extubated, although the specific details of this study are not provided due to reference restrictions 1
Evidence Supporting Low-Dose Approach
- Corticosteroids facilitate weaning from mechanical ventilation and extubation in most infants with BPD, making them the most common pharmacologic agents for this indication, as supported by the American Journal of Respiratory and Critical Care Medicine 2, 3, 4
Clinical Decision-Making Framework
- Very low birth weight infants who remain on mechanical ventilation after 1-2 weeks of age are at very high risk of developing BPD, and the decision to use corticosteroids should balance the risk of established BPD, potential adverse effects of corticosteroid therapy, and individual patient factors, according to the American Academy of Pediatrics 1, 2
- The American Academy of Pediatrics recommends considering corticosteroids for infants with severe ventilator dependence and duration, with individual patient factors taken into account 1, 2
Dosing Recommendations
- The American Academy of Pediatrics recommends dexamethasone: 0.15-0.2 mg/kg/day tapered over 7-14 days, with cumulative doses not exceeding what is necessary for extubation 1, 5
- Low-dose hydrocortisone (1 mg/kg per day) given early may increase rates of survival without BPD, particularly for infants with prenatal inflammation exposure, without adversely affecting neurodevelopmental outcomes, as suggested by the Pediatrics journal 6
Important Caveats
- The decision to use corticosteroids must be made in conjunction with the infant's parents, with clear counseling about both the risks of untreated BPD and the potential adverse effects of corticosteroid therapy, as recommended by the American Academy of Pediatrics 1
- Concomitant use of indomethacin with hydrocortisone should be avoided due to an increased risk of isolated intestinal perforation, as warned by the Pediatrics journal 1, 6
Guideline for Timing and Choice of Postnatal Glucocorticoids in Ventilator‑Dependent Preterm Infants
Optimal Timing of Initiation
Dexamethasone
Hydrocortisone
Systemic Steroid Use in Bronchopulmonary Dysplasia – Evidence‑Based Recommendations
Timing and Neurodevelopmental Risks
- The American Academy of Pediatrics advises against initiating dexamethasone within the first 7 days of life because early exposure is linked to severe neurodevelopmental injury, including cerebral palsy, neuromotor dysfunction, and impaired brain growth. 9, 10
Dose‑Response Relationship
- High‑dose dexamethasone (≥ 0.5 mg/kg/day) is associated with hippocampal neuronal degeneration, reduced hippocampal volume, and poorer neurodevelopmental outcomes; no additional therapeutic benefit over lower doses has been demonstrated. 9, 10
- Low‑dose dexamethasone (< 0.2 mg/kg/day) reliably facilitates extubation in infants with established BPD while avoiding the severe adverse effects seen with high‑dose regimens. 9, 10
Indications and Contraindications
- Routine prophylactic systemic steroids are not recommended for preterm infants at risk of BPD. 9, 10
- Systemic steroids should not be used in infants who are not ventilator‑dependent (e.g., those on nasal ventilation or supplemental oxygen alone). 9, 10
- Inhaled corticosteroids, despite reducing BPD incidence, are linked to increased mortality and therefore are not recommended for routine use. 9, 10